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Background and purpose: We have previously reported that endocannabinoids modulate 
intestinal permeability in Caco-2 cells under inflammatory conditions and hypothesised in the 
present study that endocannabinoids could also modulate intestinal permeability in 
ischemia/reperfusion. 
Experimental approach: Caco-2 cells were grown on cell culture inserts to confluence. Trans-
epithelial electrical resistance (TEER) was used to measure permeability. To generate hypoxia (0% 
O2), a GasPak™ EZ anaerobe pouch system was used. Endocannabinoids were applied to the 
apical or basolateral membrane in the presence or absence of receptor antagonists.
Key results: Complete Hypoxia decreased TEER (increased permeability) by ~35% after 4 h 
(recoverable) and ~50% after 6 h (non-recoverable). When applied either pre- or post-hypoxia, 
apical application of N-arachidonoyl-dopamine (NADA, via TRPV1), oleamide (OA, via TRPV1) 
and oleoylethanolamine (OEA, via TRPV1) inhibited the increase in permeability. Apical 
administration of anandamide (AEA) and 2-aArachidonoylglycerol (2-AG) worsened the 
permeability effect of hypoxia (both via CB1).  Basolateral application of NADA (via TRPV1), 
OA (via CB1 and TRPV1), noladin ether (NE, via PPAR), and palmitoylethanolamine (PEA, via 
PPARα) restored permeability after 4 h hypoxia, whereas OEA increased permeability (via 
PPARα).  After 6 h hypoxia, where permeability does not recover, only basolateral application 
PEA sustainably decreased permeability, and NE decreased permeability.
Conclusions and Implications: A variety of endocannabinoids and endocannabinoid-like 
compounds modulate intestinal Caco-2 permeability in hypoxiischemia/reoxygenationreperfusion, 
which involves multiple targets, depending on whether the compounds are applied to the 
basolateral or apical membrane. CB1 antagonism and TRPV1 or PPAR agonism may represent 
novel therapeutic targets against several intestinal disorders associated with increased intestinal 
permeability.
Key words: intestinal permeability; Caco-2 cells; hypoxia; ischaemia; transepithelial electrical 
resistance (TEER); endocannabinoids; cannabinoid receptor 1 (CB1); transient receptor potential 
vanilloid subtype 1 (TRPV1); peroxisome proliferator-activated receptor alpha (PPAR-); 
cannabinoid receptors; N-arachidonoyl-dopamine (NADA); oleamide (OA); anandamide (AEA); 










ANOVA analysis of variance
CB1 cannabinoid receptor one
CB2 cannabinoid receptor two
CGRP Calcitonin gene-related peptide
DMSO dimethyl sulfoxide 
ECS endocannabinoid system
EVOM epithelial tissue volt-ohm-meter
FAAH fatty acid amide hydrolase
GW6471 [(2S)-2-[[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propenyl]amino]-3-
[4-[2-(5-ethyl-2-henyl-4-azolyl)ethoxy] phenyl]propyl]-carbamic acid ethyl ester
GW9662 2-chloro-5-nitro-N-phenylbenzamide
HAEC Human aortic endothelial cell
MAGL monoacylglycerol lipase
MEME Minimal Essential Medium Eagle






O-1918 1,3-dimethoxy- 5-methyl-2-  (1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-
1-yl]benzene
PEA palmitoylethanolamine
PPAR peroxisome proliferator-activated receptor
TEER transepithelial electrical resistance






Ischemia of the gastrointestinal tract, defined as an insufficient delivery of oxygen and other 
substrates for aerobic metabolism, is a major clinical problem associated with significant 
morbidity and mortality (1). Mesenteric embolus or arteriosclerosis, strangulated intestinal hernia 
contents, necrotising enterocolitis, arterial clamping during vascular repair or visceral 
transplantation, and shock, all causing gastrointestinal ischaemia, are commonly encountered in 
clinical practice (2-5). Intestinal mucosal enterocytes, particularly at villi tips, are sensitive to 
periods of ischaemia, and develop characteristic necrotic changes such as increased paracellular 
permeability and apoptosis after as little as 1 hour (6). These changes can lead to bacterial and 
lipopolysaccharide translocation from the luminal to submucosal space, leading to further shock, 
sepsis and possibly death. Currently there are no proven clinical therapies available to prevent or 
reverse these changes other than reversal of the underlying cause.  
Endocannabinoids are lipid signalling molecules synthesised from arachidonic acid on demand 
from cell membranes (7). Endocannabinoids activate the cannabinoid receptors (CB1 and CB2) (8) 
in addition to other targets such as transient receptor potential ion channels (TRPs) (9), 
peroxisome proliferator-activated receptors (PPARs) (10) and the orphan G-protein coupled 
receptors GPR119 (11) and GPR55 (12). These target sites are expressed throughout the 
gastrointestinal tract. These ligands, the enzymes responsible for their metabolism, and target 
receptors are collectively referred to as the endocannabinoid system (ECS). The ECS has been 
shown to govern multiple physiological processes such as regulation of feeding, gastric secretion, 
intestinal motility and intestinal inflammation. Endocannabinoids and inhibitors of their 
degradation have been subject of much clinical and pre-clinical work examining their therapeutic 
potential in gastrointestinal disorders (13).
Previously, we have shown that cannabinoids modulate intestinal permeability in vitro during 
inflammatory conditions. The endocannabinoid anandamide (AEA) and 2-arachidonoylglycerol 2-
arachidonylglycerol (2-AG) increased intestinal epithelial permeability via the CB1 receptor (14, 
15).  Similarly, within a hypoxia/reperfusion model causing increased permeability of Caco-2 
monolayer, inhibition of the metabolising enzymes of AEA and 2-AG, with  the fatty acid amide 
hydrolase (FAAH) inhibitor URB597 and monoacylglycerol lipase (MAGL) inhibitor JZL184 
respectively (to enhance local endocannabinoid levels) also prevented recovery (16).  We also 
showed that knock down of the CB1 receptor had protective effects on epithelial permeability 
under cytokine-induced inflammatory (16). In contrast, we found that application of the 
  
5
endocannabinoid-like compounds palmitoylethanolamine (PEA) and oleoylethanolamine (OEA) 
prevented the cytokine-induced increases in intestinal permeability (17). Other endocannabinoid-
like compounds such as N-arachidonoyl dopamine (NADA), noladin ether (NE), oleamide (OA) 
and virodhamine (VD) have not yet been examined for effects on  intestinal permeability in Caco-
2 cells.
As the effects of AEA, 2-AG, PEA and OEA on the permeability of the human gut have been 
established under normal and inflammatory conditions, we sought to examine their effects on 
hypoxia-induced increases in permeability and the receptor mechanisms of action. Additionally, 
we investigated the effects of other endocannabinoid-like compounds on intestinal permeability 
for the first time.  Our hypothesis was that some endocannabinoids would reduce the increased 
intestinal permeability in Caco-2 cells observed after hypoxia.
2.0 Methods
Caco-2 cells (European Collection of Cell Culture, Wiltshire, UK; passages 62-86) were used as 
an in vitro model of intestinal epithelial cells and were cultured in Minimal Essential Medium 
Eagle (MEME) supplemented with 10% foetal bovine serum, 1% penicillin/streptomycin and L-
glutamine at 37ºC in 5% CO2 and 95% air. Cells were seeded at 2x104 per ml onto 6.4 mm 
diameter transparent polystyrene membrane inserts with 0.4 µm pore size in 24 well plates (BD 
Biosciences, UK) and grown for 14 to 18 days until fully confluent. Transepithelial electrical 
resistance (TEER) was measured as an indicator of cell confluence and intercellular permeability 
using a voltoham2 meter (EVOM2) (World Precision Instruments, Sarasota FL, USA). 
2.1 Effects of hypoxia and reoxygenation on Caco-2 permeability 
Complete Hhypoxic (0% O2) conditions, as occurs after embolic blockage leading to total 
ischaemia of sections of the intestine, were mimicked using a GasPak™ EZ Anaerobe Pouch 
System (Beckton-Dickinson, Oxon, UK) for up to 8 hours. Using the pouch system, anoxia is 
achieved within about 20 min.  After the hypoxic conditions had ended, the media was changed 
and inserts were returned to the incubator for a period of reoxygenation  reperfusion of up to 72 
hours. TEER values were measured at baseline (0 h), and then at regular time points. 
2.2 Effects of endocannabinoids on increased intestinal permeability caused by hypoxia 
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AEA, 2-AG, PEA, OEA, NADA, NE, OA and VD (all 10µM based on our previous observations 
that only micromolar concentrations of cannabinoids are effective in this model, (17, 18) or 
vehicle (0.1% ethanol) were applied to the apical (representing the intestinal lumen) or basolateral 
(representing the microcirculation) membrane at the onset of hypoxia (0 h) or at the onset of 
reoxygenationreperfusion. Although this is above the reported tissue concentrations of 
endocannabinoids and endocannabinoid-like substances measured in the gut (Fu et al., 2007; 
Igarashi et al., 2015), it is not known what the local concentrations of these compounds might be 
when they are produced at the cell membrane.  When endocannabinoids were added to fresh 
media at the beginning of reoxygenationreperfusion periods, media was not changed until the end 
of the 72 h experimental period (thus they were present throughout the reoxygenation period).  
To investigate the potential target sites of action, the following receptor antagonists were co-
applied with endocannabinoids as previously published (16-19): AM251 (CB1 antagonist), 
AM630 (CB2 antagonist), GW9662 (PPARγ antagonist), GW6471 (PPAR antagonist) (all 
100nM), capsazepine (TRPV1 antagonist,) (1μM) and proposed cannabinoid receptor antagonist 
O-1918 (1μM). Appropriate vehicles (0.1% ethanol or 0.01% dimethyl sulfoxide (DMSO)) were 
applied to control inserts. 
2.3 RT-PCR
The presence of predicted sites of action was investigated at the mRNA level using reverse 
transcription followed by polymerase chain reaction (RT-PCR) as previously published (20, 21).  
Human astrocytes (HAs) were used as a positive control known to express all the target sites of 
action of interest (21).  Total RNA was extracted from HAs and human aortic endothelial cells 
(HAECs) using Allprep DNA/RNA kit with on column DNaseI treatment (Qiagen, Germany). 
Reverse transcription with (+) and without reverse transcriptase (-) was performed in 20 µl final 
volume using 2 µg of total RNA and random primers with the High Capacity cDNA Reverse 
Transcription Kit (Life Technologies, UK). PCR reactions were carried out in a final volume of 25 
µl with Zymotaq (ZymoResearch, USA) using 2 µl of reverse transcription product as the 
template. After 5 min at 95oC, PCRs were performed for 40 cycles except those for calcitonin 
gene-related peptide receptor (CGRPR) and CB2R that were carried out for 60 cycles. The cycles 
included 30 sec at 95oC, 30 sec at the annealing temperature that was optimal for each primer pair 
(56oC for CB1R and CB2R; 60oC for HPRT; 58oC for TRPV1; 61oC for CGRPR) and a final 
extension step of 30 sec at 72oC. Amplification products were separated by gel electrophoresis 
  
7
through ethidium bromide stained 2% agarose (CB1R, CB2R, TRPV1, CGRPR and HPRT) and 
visualised using a Biorad Chemidoc.
2.4 Chemicals and reagents
All chemicals and reagents used in these experiments were purchased from Sigma Chemical 
(Poole, UK) unless otherwise mentioned. AEA, 2-AG, PEA, OEA, NADA, VD, NE, OA and the 
receptor antagonists AM251, AM630, GW9662, GW6471, capsazepine and O-1918 were 
purchased from Tocris Biotechne (Bristol, UK) and dissolved in ethanol to a stock concentration 
of 10mM, with further dilutions in fresh MEME. All antagonists were dissolved in DMSO to 
10mM, with further dilution made in MEME. 
2.5 Statistical analysis
The effects of endocannabinoids on TERR was statistically analysed by 2-way ANOVA with 
Dunnett’s multiple comparison test comparing data against the vehicle control within that 
experiment.  The effects of endocannabinoids in the presence of antagonists was statistically 
analysed by 2-way ANOVA with Dunnett’s multiple comparison test comparing data against the 




3.1 Effects of hypoxia on Caco-2 monolayer permeability 
Increasing durations of complete hypoxia (1-8 h) caused greater decreases in TEER increases in 
permeability as suggested by with progressive falls decreases in TEER observed for every 
additional hour of complete oxygen deprivation (Ffigure 1). The fall in TEER after hypoxia was 
recoverable to baseline after up to 4 h of hypoxia (Ffigure 1A).  However, the permeability of 
cells exposed to 6 or 8 h of hypoxia did not recover to baseline by 72 h (Ffigure 1B).
3.2 Effects of endocannabinoids on hypoxia-induced falls in TEER 
When endocannabinoids were applied apically to Caco-2 cells prior to 4 h hypoxia, NADA, OEA 
and OA all significantly prevented the fall in TEER compared to vehicle (Ffigure 2A, figure 3A). 
Apically applied 2-AG and AEA caused a greater reduction in TEER compared to vehicle 
(Ffigure 2A). NE, VD and PEA had no significant effect on the fall in TEER compared to vehicle 
(Ffigure 2A, figure 3A).  
When applied apically at the end of the 4 h hypoxia, NADA, OEA and OA caused a faster 
recovery to baseline compared to vehicle as denoted by significantly lower % falls in TEER 
(Ffigure 2B, figure 3B), 2-AG and AEA caused a delayed recovery  of TEER (significantly 
greater % falls in TEER) compared to vehicle (Ffigure 2B), while NE, VD and PEA had no effect 
on TEER when applied apically.  
When applied basolaterally prior to the onset of hypoxia, OA, NADA, NE and PEA prevented 
falls in TEER compared to vehicle (Ffigure 2C, , figure 3C), OEA caused a greater increase in 
permeability (Ffigure 2C), and OEA, VD, AEA and 2-AG had no effect (Ffigure 2C, figure 3C).
When applied basolaterally at the end of the 4 h hypoxia, PEA, NE, NADA and OA improved 
recovery to baseline compared to vehicle (Ffigure 2D, figure 3D), OEA worsened permeability 
(Ffigure 2D), while AEA, VD and 2-AG had no effect.
The effects of all endocannabinoids at each membrane are summarised in table 1.
3.3 Receptor mechanism of action for endocannabinoids
As shownfound in Figure 3, apical application of NADA (post-hypoxia) significantly limited the 
fall in TEER caused by hypoxia compared to vehicle (Ffigure 4BA), and this effect of NADA was 
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prevented bysignificantly inhibited in the presence of the TRPV1 antagonist capsazepine (but not 
by antagonism of CB1, CB2, the O-1918-sensitive cannabinoid target, PPARα or ).  The apical 
application of OA limited the fall in TEER, and this effect was also significantly inhibited by 
capsazepine (figure 4AB).  Similarly, the effects of OEA at the apical membrane were prevented 
by the TRPV1 antagonist capsazepine (Ffigure 4C). The effect of AEA and 2-AG at increasing 
permeability (decreasing TEER) were blocked by the CB1 receptor antagonist AM251 (Figure 4C).  
To summarise, at the apical membrane, NADA, OA and OEA limit the permeability effects of 
hypoxia, all through TRPV1, while AEA and 2-AG cause further increases in permeability via the 
CB1 receptor. 
The presence of these target sites at the RNA level in CaCo2 cells was tested by , RT-PCR using 
relevant primers (Figure 4D). This analysis confirmed the presence of PPARα or , CB1, CB2, 
TRPV1 and GPR55 receptors in CaCo-2 cells; expression of these targets in human astrocytes (21) 
was used as a positive control (Figure 4D).
At the basolateral membrane, the positive effects of NADA on hypoxia-induced permeability 
were inhibited by the TRPV1 antagonist capsazepine (figure 5A). The positive effects of OA were 
inhibited by the TRPV1 antagonist capsazepine and the CB1 receptor antagonist AM251 (figure 
5B). The positive effects of NE (Figure 5C) and PEA (Figure 5D) on hypoxia-induced 
permeability were prevented by the PPARα antagonist GW6471. The effect of basolateral 
application of OEA to further increase CaCo-2 permeability was inhibited by the PPARα 
antagonist GW6471 but not the TRPV1 antagonist capsazepine. To summarise, at the basolateral 
membrane, NADA and OA limit the permeability effects of hypoxia through TRPV1 while NE 
and PEA limit the permeability effects of hypoxia through PPARα. However, OEA further 
increases permeability at the basolateral membrane, also via PPARα.
3.4 Effects of endocannabinoids on increased permeability caused by 6 h hypoxia 
As our first experiments had demonstrated NADA, OA and OEA (all through TRPV1) limit the 
permeability effects of 4 h hypoxia (which is recoverable), we assessed their effects after 6 hours 
of hypoxia, where permeability does not recover over 72 h.  However, in this model, we found 
that apical application of NADA, OA and OEA had no effect on recovery compared to vehicle 
(figure 6A).  
Similarly, as NADA, NE, PEA and OA all improved permeability when applied basolaterally 
after 4 hours of hypoxia, we tested their effects after 6 hours of hypoxia. In this model, PEA 
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(which works through PPARα) caused a recovery in TEER throughout the 72 h study period 
compared to vehicle (figure 6B). NE (which also works through PPARα) increased TEER at 8 
hours, though this was transient, with no difference compared to vehicle by 10 h (figure 6B). OA 
and NADA (which work through TRPV1) had no effect on TEER compared to vehicle in the 6 h 
hypoxia model.
4.0 Discussion
In this study, we sought to investigate for the first time the effects of a range of endocannabinoids 
and endocannabinoid-like compounds on hypoxia-induced changes in membrane permeability.  
This study showed activation of the TRPV1 receptor by endocannabinoids (OEA, NADA and 
OA) at the apical membrane decreases intestinal permeability, while activation of the CB1 
receptors at the apical membrane (by AEA and 2-AG) increases intestinal permeability. At the 
basolateral membrane, endocannabinoids (PEA, NADA, NE and OA) decrease intestinal 
permeability through activation of PPARα, TRPV1 and CB1.  The expression of these targets in 
our cell line was confirmed by RT-PCR.  VD does not appear to affect intestinal Caco-2 
permeability.  These findings add to our previous body of working demonstrating the ability of the 
endocannabinoid system to modulate intestinal permeability in cells and tissues of the intestine.
We have previously demonstrated in a model of inflammation-induced hyperpermeability that 
OEA decreased permeability at the apical membrane through TRPV1 (17).  In the present model 
of ischaemia-reperfusionhypoxia-reoxygenation-induced hyperpermeability, we also found that 
both apical and basolateral application of OA or NADA, or apical application of OEA, prevented 
the increased permeability induced by 4 h complete hypoxia (0% O2), all through TRPV1 
activation, suggesting this receptor may be expressed at both membrane of differentiated CaCo2 
cells.  TRPV1 receptors have previosuly been shownfound to play a major role in the regulation of 
digestive tract function (22, 23).  Our findings are in agreement with Du et al (2010) who showed 
that TRPV1 agonists including capsaicin, genistein, and isoflavone have protective role against 
gastric ischemia and reperfusion when administered prior to reperfusion (24). Capsaicin also 
protects against damage caused by ischemia and reperfusion in the kidneys (25), lungs (26), brain 
(27) and heart (28).  
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PPAR is highly expressed in human intestine and plays a key role in the reduction of intestinal 
inflammation (29, 30), decreasing intestinal permeability (31) and cell viability (32). We 
previously found in a model of inflammation-induced hyperpermeability that PEA decreased 
permeability through PPARα (17) and similar findings were observed in the present study with 
hypoxia as the stimulus for increasing permeability. NE application at the basolateral also 
prevented increased permeability through PPARα. The fact that a role for PPARα activation was 
only observed when endocannabinoids were applied to the basolateral membrane may reflect a 
more basolateral location of the nucleus in these cells, however there could be other explanations 
for these findings such as differential expression of the hydrolysing enzymes or transport 
processes of the endocannabinoid system across polarised cells such as intestinal epithelium. 
These data are in agreement with in vivo data showing PPAR agonism reduced intestinal damage 
and inflammation caused by ischemia and reperfusion (33) (34). Similarly, activation of PPAR 
improves ischemia and reperfusion injury in other organs and systems including the kidneys (34, 
35), heart (36) and brain (37).  Interestingly, we found that PEA does not have an anti-
inflammatory effect (reduce cytokine secretion) in Caco-2 cells (38), suggesting that the positive 
effects of OEA and PEA (and possibly NE) on cellular permeability are separate from any anti-
inflammatory effects.  
Although basolateral application of PEA and NE improved the Caco-2 permeability response to 
oxygen deprivation through PPAR activation, we found that basolateral application of OEA had 
the opposite effect, also apparently mediated by PPAR.  Similarly, we previously found that CB1 
activation by phytocannabinoids decreased Caco-2 permeability while CB1 activation by 
endocannabinoids increased permeability (19) (18). Our more recent unpublished research 
suggests this is due to agonist bias at the CB1 receptor, and it is possible that agonist bias also 
occurs at PPAR.
Although PEA, NADA, OA and NE all had protective effects on intestinal permeability in the 4 
hour, recoverable model of hypoxia, after 6 hour hypoxia, only basolateral application of PEA or 
NE were able to partially improve permeability.  This is consistent with our previous finding that 
basolateral application of PEA was able to decrease permeability 72 h after the induction of 
inflammation via PPARα (17), and suggests that PEA might be effective as a therapeutic after 
prolonged periods of ischaemia or inflammation, such as during surgery.  Since PPARα activation 
is the common mechanism of action in the present study, it suggests that PPARα may be a more 
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robust therapeutic target (than TRPV1, whose activation was only beneficial in the 4 h model) for 
treating increased intestinal permeability.  This may be because we recently showed that TRPV1 
is downregulated in Caco-2 cells or in human colonic tissue after inflammation(39) (Couch et al., 
2019, in press).
CB1 receptors are expressed in the gastrointestinal tract epithelium (40, 41) and in our Caco-2 
cells, and are activated by many endocannabinoids including AEA, 2-AG (30, 42), OA (43) and 
NADA (44). In this study, we found that activation of CB1 at the apical membrane with AEA and 
2-AG worsened hypoxia-induced hyper-permeability, consistent with our previous observations 
examining their effect on inflammation-induced hyper-permeability (18). Of interest, NADA, NE 
and VD have been shown previously to be able to activate CB1 (45), however these compounds 
did not have CB1 mediated effects in our model. This could be due to differences in central versus 
peripheral/epithelial CB1 (46), or might reflect agonist bias properties of CB1 in our cell type as we 
have already observed for endocannabinoids versus phytocannabinoids.  In other organs, CB1 
receptor antagonism decreases infarct size in cerebral ischemia (47, 48) and preserves hepatocyte 
function in ischemic liver injury (49). Our data from this and previous studies (18) (16) suggests 
that CB1 antagonism may prevent the hyperpermeability caused by ischaemia and hypoxia. This 
may be a useful clinical tool for prophylaxis against the effects of clinical gastrointestinal 
ischaemia.
In conclusion, this is the first report of endocannabinoids modulating Caco-2intestinal 
permeability through numerous targets in a recoverable model of intestinal epithelial 
hypoxiaischemia and reperfusionreoxygenation.  Endocannabinoid activation of TRPV1 and 
PPAR has positive effects on Caco-2 permeability, while CB1 activation at the apical membrane 
increases permeability. CB1 antagonism and TRPV1 or PPAR agonism may represent novel 
therapeutic targets against several intestinal disorders associated with increased intestinal 
permeability. Endocannabinoid effects on permeability should now be investigated in ex vivo 
models of inflammation and ischaemia and also in animal models to evaluate potential roles in 
disease modification and prophylaxis for maintenance of intestinal mucosal integrity.
Conflicts of interest
None.SOS is a scientific advisor for the Centre for Medicinal Cannabis, Artelo Bioscience and 






Figure 1. The effect of short-term and recoverable (1-4 h, A) and non-recoverable (6 and 8 h, B) 
hypoxia and reoxygenationreperfusion on Caco-2 permeability. Data are given as means ± S.E.M. 
(n=3).
Figure 2. The effects of endocannabinoids and endocannabinoid-like compounds (anandamide 
(AEA), 2-arachidonylglycerol (2-AG), oleoylethanolamine (OEA) and palmitoylethanolamine 
(PEA), all 10µM) applied before (A, C) or after 4 h hypoxia (B, D) to the apical (A,B) or 
basolateral (C,D) membrane of Caco-2 cells.  Arrows denote the time of application of 
endocannabinoids and the solid line denotes the period of hypoxia.  Data are given as means and 
standard error bars S.E.M. (n=3) and was analysed by 2-way ANOVA with Dunnett’s multiple 
comparison test comparing data against the vehicle control (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001).
Figure 3. The effects of endocannabinoids (N-arachidonyldopamine (NADA), virodhamine (VD), 
noladine ether (NE), and oleamide (OA), all 10µM) applied before 4 h hypoxia (A, C) or after 4 h 
hypoxia (B, D) to the apical (A,B) or basolateral (C,D) membrane of Caco-2 cells.  Arrows denote 
the time of application of endocannabinoids and the solid line denotes the period of hypoxia.  Data 
are given as means and standard error bars S.E.M. (n=3) and was analysed by 2-way ANOVA 
with Dunnett’s multiple comparison test comparing data against the vehicle control (*P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001).
Figure 4. Mechanisms of action for N-arachidonyldopamine (NADA, (A), oleamide (OA, B) and 
anandamide, 2-arachidonylglycerol (2-AG) and oleoylethanolamine (OEA, (C) applied to the 
apical membrane after 4 h hypoxia in the presence of various receptor antagonists.  Arrows denote 
the time of application of endocannabinoids and the solid line denotes the period of hypoxia.  Data 
are given as means and standard error bars S.E.M. (n=3) and was analysed by 2-way ANOVA 
with Dunnett’s multiple comparison test comparing data against the endocannabinoid alone 
control (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).  D. RT-PCR showing the presence of 
CB1, CB2, PPAR and , TRPV1 and CGRP receptors in CaCo-2 cells. Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) was used as a house-keeping gene. The columns shown with + 
are with reverse transcriptase and those with – are without reverse transcriptase. Human astrocytes 
(HA) are shown as a positive control for cannabinoid target expression. 
Figure 5. Mechanisms of action for N-arachidonyldopamine (NADA, (A), oleamide (OA, B) 
noladin ether (NE, C), and palmitoylethanolamine (PEA) and oleoylethanolamine (OEA, (D) 
applied to the basolateral membrane after 4 h hypoxia in the presence of various receptor 
antagonists. Arrows denote the time of application of endocannabinoids and the solid line denotes 
the period of hypoxia.  Data are given as means and standard error bars S.E.M. (n=3) and was 
analysed by 2-way ANOVA with Dunnett’s multiple comparison test comparing data against the 
endocannabinoid alone control (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).
Figure 6. A. The effects of apical application of N-arachidonyldopamine (NADA), 
oleoylethanolamine (OEA) and oleamide (OA) on Caco-2 permeability after 6 h hypoxia.  B. The 
effects of basolateral application of NADA, noladin ether (NE), palmitoylethanolamine (PEA) and 
OA on Caco-2 permeability after 6 h hypoxia (A). Data are given as means and standard error 
bars S.E.M. (n=3) and was analysed by 2-way ANOVA with Dunnett’s multiple comparison test 






Effect on IP Target Effect on IP Target
AEA   permeability CB1 No response      -
2-AG   permeability CB1 No response      -
OEA   permeability TRPV1    permeability PPAR
PEA No response      -    permeability PPAR
NADA   permeability TRPV1    permeability TRPV1
NE No response      -    permeability PPAR
OA   permeability TRPV1    permeability CB1 & TRPV1
VD No response      - No response         -
Table 1 Summary of the target sites of action of endocannabinoids on intestinal permeability (IP) 
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